Dendritic Cell Ontogeny and Clinical Application

Lecture Outcome Number Four

Overview of Dendritic Cell Ontogeny

  • Dendritic Cells (DCs): Specialized immune cells crucial for initiating and modulating immune responses.
  • Importance in clinic: Understanding their development allows for laboratory cultivation of large quantities for therapeutic use.

Source of Immune Cells

  • Immune system originates from Bone Marrow.
  • Derived from Multipotent Hemopoietic Stem Cells which can differentiate into:
    • Myeloid Cells: Leads to granulocytes, macrophages, red blood cells, and platelets.
    • Lymphoid Cells: Leads to T cells, B cells, and NK cells.

Dendritic Cell Origins

  • Dendritic Cells: Unconventional in origin; can derive from both myeloid and lymphoid pathways:
    • Myeloid Pathway: Commonly associated with monocyte differentiation.
    • Lymphoid Pathway: Can also give rise to DCs, contrary to assumptions that they are exclusively myeloid.
  • Types of Dendritic Cells:
    • Conventional Dendritic Cells (cDC): Can arise from both pathways.
    • Plasmacytoid Dendritic Cells (pDC): Part of lymphoid origin.

Key Cytokine in Dendritic Cell Development

  • FLT3 Ligand:
    • Signals precursor cells to differentiate into dendritic cells.
    • Immature immune cell precursors express FLT3 (the receptor).
    • Binding of FLT3 ligand initiates dendritic cell differentiation.
  • Inflammatory Dendritic Cells: Generated from Monocytes in the presence of GM-CSF and IL-4.

Clinical Application of Dendritic Cells

  • Dendritic cells are rare, making them challenging to study and utilize effectively.
  • Method to generate large quantities:
    • Cultivating monocytes with GM-CSF and IL-4 to produce inflammatory Dendritic Cells.
    • Employing human stem cells with FLT3 ligand or other cytokines to engender various types of dendritic cells.
  • Usage in therapy and potential as vehicles for vaccines against diseases (e.g., cancer).
    • The process involves:
    • Culturing dendritic cells with specific cytokines.
    • Pulsing them with an antigen before injection into humans.
    • The injected DCs migrate to lymph nodes and activate CD8 T Cells, potentially leading to tumor cell destruction.

Specific Dendritic Cell Types for Different Vaccinations

  • Cancer Vaccination:
    • Require DCs that promote Th1 immunity and cytotoxic T cell activation, particularly Type 1 Dendritic Cells (DC1).
  • Worm Vaccination:
    • Favor Th2 response; hence, Type 2 Dendritic Cells (DC2) are preferred.

Evidence and Challenges in Dendritic Cell Therapy

  • Current use in clinical settings is limited; however, experimental results show potential:
    • Case Study: An anecdotal account of a patient with melanoma who showed complete regression of tumors following several immunizations with inflammatory DCs.
    • Variability in response among patients (not universally effective).
  • For further study: Advanced immunology course (Immunology 3042) in the following semester.

Broader Definitions of Antigen Presenting Cells (APCs)

  • Traditional APCs include Dendritic Cells, Macrophages, and B Cells.
  • Expanding definitions: Evidence suggests other immune cells may present antigens, including:
    • Mast Cells
    • Basophils
    • Eosinophils
    • Innate Lymphoid Cells (ILC3s)
    • Emerging research highlights the antigen-presenting capabilities of ILCs.

Conclusion and Reflection

  • Understanding dendritic cells is crucial for developing effective immune responses.
  • Emphasized the importance of DC diversity and ontogeny in both laboratory and clinical contexts.
  • Acknowledged unconventional views on the role of other immune cells in antigen presentation.

Summary of Learning Objectives

  • Contextualize antigen presentation within the immune response framework.
  • Evaluate the importance of major professional antigen-presenting cells (APCs).
  • Compare and contrast types of dendritic cells and their activation states.
  • Analyze dendritic cell lineage diversity and their implications for immunotherapy.